89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focusing on liver and cardiometabolic disease therapies, has announced inducement grants for three new employees. The Compensation Committee approved non-qualified stock options to purchase 267,000 shares of common stock on August 1, 2025.
The grants, made under the company's 2023 Inducement Plan, will vest over four years, with 25% vesting after one year and the remainder vesting in 12 quarterly installments. The exercise price equals the closing price of 89bio's stock on the grant date. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
[]89bio (Nasdaq: ETNB), un'azienda biofarmaceutica in fase clinica specializzata in terapie per malattie epatiche e cardiometaboliche, ha annunciato l'assegnazione di stock option come incentivo per tre nuovi dipendenti. Il Comitato per la Compensazione ha approvato opzioni su azioni non qualificate per l'acquisto di 267.000 azioni ordinarie con scadenza il 1° agosto 2025.
Le assegnazioni, effettuate nell'ambito del Piano di Incentivi 2023 della società, matureranno in un periodo di quattro anni, con il 25% che matura dopo un anno e il resto in 12 rate trimestrali. Il prezzo di esercizio corrisponde al prezzo di chiusura delle azioni di 89bio alla data di assegnazione. Queste assegnazioni sono state effettuate in conformità con la Regola 5635(c)(4) del Nasdaq.
89bio (Nasdaq: ETNB), una compañía biofarmacéutica en etapa clínica enfocada en terapias para enfermedades hepáticas y cardiometabólicas, ha anunciado concesiones de incentivos para tres nuevos empleados. El Comité de Compensación aprobó opciones sobre acciones no calificadas para comprar 267,000 acciones comunes con fecha de vencimiento el 1 de agosto de 2025.
Las concesiones, realizadas bajo el Plan de Incentivos 2023 de la empresa, se consolidarán durante cuatro años, con un 25% consolidado tras un año y el resto en 12 cuotas trimestrales. El precio de ejercicio es igual al precio de cierre de las acciones de 89bio en la fecha de concesión. Estas concesiones se realizaron conforme a la Regla 5635(c)(4) de Nasdaq.
89bio (나스닥: ETNB)는 간 및 심장대사 질환 치료제에 중점을 둔 임상 단계의 생명공학 제약 회사로, 세 명의 신규 직원에게 유인 주식 옵션을 부여했다고 발표했습니다. 보상 위원회는 2025년 8월 1일에 만료되는 267,000주의 보통주를 구매할 수 있는 비자격 주식 옵션을 승인했습니다.
이 부여는 회사의 2023년 유인 계획에 따라 이루어졌으며, 4년에 걸쳐 권리가 취득되며, 1년 후 25%가 취득되고 나머지는 12분기 분할로 취득됩니다. 행사가격은 부여일에 89bio 주식의 종가와 동일합니다. 이 부여는 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
89bio (Nasdaq : ETNB), une société biopharmaceutique en phase clinique spécialisée dans les thérapies pour les maladies du foie et cardiométaboliques, a annoncé des attributions incitatives pour trois nouveaux employés. Le comité de rémunération a approuvé des options d'achat d'actions non qualifiées portant sur 267 000 actions ordinaires, avec une échéance au 1er août 2025.
Ces attributions, réalisées dans le cadre du Plan d'incitation 2023 de l'entreprise, seront acquises sur une période de quatre ans, avec 25 % acquis après un an et le reste en 12 versements trimestriels. Le prix d'exercice correspond au cours de clôture de l'action 89bio à la date d'attribution. Ces attributions ont été effectuées conformément à la règle 5635(c)(4) du Nasdaq.
89bio (Nasdaq: ETNB), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Fokus auf Therapien für Leber- und kardiometabolische Erkrankungen, hat Zuteilungen als Anreiz für drei neue Mitarbeiter bekannt gegeben. Der Vergütungsausschuss genehmigte nicht qualifizierte Aktienoptionen zum Kauf von 267.000 Aktien des Stammkapitals mit Ablaufdatum 1. August 2025.
Die Zuteilungen, die im Rahmen des Inducement-Plans 2023 des Unternehmens erfolgen, werden über vier Jahre erworben, wobei 25 % nach einem Jahr und der Rest in 12 vierteljährlichen Raten vesten. Der Ausübungspreis entspricht dem Schlusskurs der 89bio-Aktie am Zuteilungsdatum. Diese Zuteilungen erfolgten gemäß der Nasdaq-Listing-Regel 5635(c)(4).
- None.
- None.
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 267,000 shares of the Company’s common stock to three new employees (the “Inducement Grants”) on August 1, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The Company is in Phase 3 trials for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, including patients with compensated cirrhosis, and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The Company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the Company on LinkedIn.
Investor Contacts:
Annie Chang
89bio, Inc.
investors@89bio.com
Eva Bilange
89bio, Inc.
eva.bilange@89bio.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
What stock options did 89bio (ETNB) grant to new employees in August 2025?
What is the vesting schedule for 89bio's August 2025 inducement grants?
What is the exercise price for 89bio's August 2025 inducement grants?
Why did 89bio issue these stock options in August 2025?
